ArticleGene therapy2009
Polymeric gene delivery of ischemia-inducible VEGF significantly attenuates infarct size and apoptosis following myocardial infarct.
Article in Gene therapy, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 57 citations in OpenAlex.
- Gene Therapy for Cardiovascular Disease: Clinical Perspectives.Yonsei medical journal · 2024Review
- Cardiac aorta-derived extracellular matrix scaffold enhances critical mediators of angiogenesis in isoproterenol-induced myocardial infarction mice.Journal of materials science. Materials in medicine · 2021Article
- Water-Soluble Polymer AssistsPain research & management · 2018Article
- Gene delivery of hypoxia-inducible VEGF targeting collagen effectively improves cardiac function after myocardial infarction.Scientific reports · 2017Article
- Gene delivery nanoparticles to modulate angiogenesis.Advanced drug delivery reviews · 2017Review
- Hypoxia-inducible tumour-specific promoters as a dual-targeting transcriptional regulation system for cancer gene therapy.Ecancermedicalscience · 2017Review
- Functional polymers of gene delivery for treatment of myocardial infarct.Journal of controlled release : official journal of the Controlled Release Society · 2014Review
- Emulsion electrospun nanofibers as substrates for cardiomyogenic differentiation of mesenchymal stem cells.Journal of materials science. Materials in medicine · 2013Article
- Hypoxia-based strategies for angiogenic induction: the dawn of a new era for ischemia therapy and tissue regeneration.Organogenesis · 2013Review
- Post-translational regulation of a hypoxia-responsive VEGF plasmid for the treatment of myocardial ischemia.Biomaterials · 2013Article
- Targeted gene delivery to ischemic myocardium by homing peptide-guided polymeric carrier.Molecular pharmaceutics · 2013Article
- Post-translational regulated and hypoxia-responsible VEGF plasmid for efficient secretion.Journal of controlled release : official journal of the Controlled Release Society · 2012Article
- Magnetic resonance imaging (MRI) assessment of ventricular remodeling after myocardial infarction in rabbits.Comparative medicine · 2012Article
- Biomaterials to gene delivery.Journal of controlled release : official journal of the Controlled Release Society · 2011Article
- Nanoparticles targeting the infarcted heart.Nano letters · 2011Article
- VEGF/SDF-1 promotes cardiac stem cell mobilization and myocardial repair in the infarcted heart.Cardiovascular research · 2011Article
- Gene therapy for ischemic heart disease.Journal of molecular and cellular cardiology · 2011Review
- Hypoxia-inducible vascular endothelial growth factor-engineered mesenchymal stem cells prevent myocardial ischemic injury.Molecular therapy : the journal of the American Society of Gene Therapy · 2011Article
- Bioreducible polymer-transfected skeletal myoblasts for VEGF delivery to acutely ischemic myocardium.Biomaterials · 2011Article
- Ligation of the left circumflex coronary artery with subsequent MRI and histopathology in rabbits.Journal of the American Association for Laboratory Animal Science : JAALAS · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
Abstract
The development of clinically beneficial myocardial gene therapy has been slowed by reliance on the use of viral carriers and non-physiologic, constitutive gene expression. To specifically address these issues, we have developed a non-viral gene carrier, water-soluble lipopolymer (WSLP), and an ischemia-inducible plasmid construct expressing vascular endothelial growth factor (VEGF), pRTP801-VEGF, to treat myocardial ischemia and infarction. Rabbits underwent ligation of the circumflex artery followed by injection of (a) an ischemia-inducible VEGF gene construct in a WSLP carrier; (b) a constitutively expressed, or unregulated, SV-VEGF gene construct in a WSLP carrier; (c) WSLP carrier alone; or (d) no injection therapy. Following 4 weeks treatment, ligation alone resulted in infarction of 48+/-7% of the left ventricle. With injection of WSLP carrier alone, 49+/-6% of the left ventricle was infarcted (P=NS). The constitutively expressed gene construct, SV-VEGF, reduced the infarct size to 32+/-7% of the left ventricle (P=0.007). The ischemia-inducible gene construct, RTP801-VEGF, further reduced the infarct size to 13+/-4% of the left ventricle (P<0.001). The use of a non-viral carrier to deliver an ischemia-inducible VEGF construct is effective in the treatment of acutely ischemic myocardium.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.